company background image
AZN logo

AstraZeneca LSE:AZN Stock Report

Last Price

UK£117.38

Market Cap

UK£182.0b

7D

0.7%

1Y

7.3%

Updated

06 Oct, 2024

Data

Company Financials +

AZN Stock Overview

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance2/6
Financial Health3/6
Dividends4/6

AstraZeneca PLC Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AstraZeneca
Historical stock prices
Current Share PriceUK£117.38
52 Week HighUK£133.88
52 Week LowUK£94.61
Beta0.17
11 Month Change-7.21%
3 Month Change-2.54%
1 Year Change7.27%
33 Year Change32.05%
5 Year Change69.72%
Change since IPO1,667.77%

Recent News & Updates

Recent updates

AstraZeneca (LON:AZN) Has Announced A Dividend Of $0.776

Jul 30
AstraZeneca (LON:AZN) Has Announced A Dividend Of $0.776

Should You Be Adding AstraZeneca (LON:AZN) To Your Watchlist Today?

Jul 04
Should You Be Adding AstraZeneca (LON:AZN) To Your Watchlist Today?

Shareholder Returns

AZNGB PharmaceuticalsGB Market
7D0.7%-0.7%-0.8%
1Y7.3%4.5%9.1%

Return vs Industry: AZN exceeded the UK Pharmaceuticals industry which returned 4.5% over the past year.

Return vs Market: AZN underperformed the UK Market which returned 9.1% over the past year.

Price Volatility

Is AZN's price volatile compared to industry and market?
AZN volatility
AZN Average Weekly Movement2.6%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement4.7%
10% most volatile stocks in GB Market9.5%
10% least volatile stocks in GB Market2.6%

Stable Share Price: AZN has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: AZN's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199289,900Pascal Soriotwww.astrazeneca.com

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease.

AstraZeneca PLC Fundamentals Summary

How do AstraZeneca's earnings and revenue compare to its market cap?
AZN fundamental statistics
Market capUK£181.97b
Earnings (TTM)UK£4.91b
Revenue (TTM)UK£37.43b

37.1x

P/E Ratio

4.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AZN income statement (TTM)
RevenueUS$49.13b
Cost of RevenueUS$8.54b
Gross ProfitUS$40.59b
Other ExpensesUS$34.15b
EarningsUS$6.44b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 12, 2024

Earnings per share (EPS)4.15
Gross Margin82.62%
Net Profit Margin13.11%
Debt/Equity Ratio81.8%

How did AZN perform over the long term?

See historical performance and comparison

Dividends

1.9%

Current Dividend Yield

71%

Payout Ratio